<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29425831</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>153</Volume><PubDate><Year>2018</Year><Month>May</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>GS-9620 inhibits enterovirus 71 replication mainly through the NF-&#x3ba;B and PI3K-AKT signaling pathways.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>48</EndPage><MedlinePgn>39-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2018.02.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(17)30701-5</ELocationID><Abstract><AbstractText>Human enterovirus 71 (EV71) is the second most common cause of hand, foot, and mouth disease (HFMD), which can occur as a severe epidemic especially among children under 5-years old. New and improved treatment strategies to control EV71 infection are therefore urgently required. The heterocyclic compound GS-9620, a potent and selective agonist of Toll-like receptor 7 (TLR7), has been reported to activate plasmacytoid dendritic cells (pDCs), and suppress HBV as well as HIV replication. In this study, we indicated that GS-9620 also could inhibit EV71 replication in the mouse model of EV71 infection. With three-days treatment after EV71 infection, the levels of proinflammatory cytokines/chemokines, like IFN-&#x3b1;, IFN-&#x3b3; and MCP-1, were sharply reduced in serum compared to those without treatment. Furthermore, GS-9620 activated TLR7 in the limb muscle cells, which stimulated the NF-&#x3ba;B and PI3K/AKT signaling pathways. When NF-&#x3ba;B or PI3K/AKT inhibitors were used, the antiviral effect of the GS-9620 was impacted. Overall, our data implied GS-9620 probably activates NF-&#x3ba;B and PI3K/AKT signaling pathways to clear the virus.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Binbin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guangchao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Pin</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yunlin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiangning</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China. Electronic address: ljn_zb03038@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Chuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC) &amp; Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Key Laboratory of Human Disease Comparative Medicine Ministry of Health, Beijing, PR China. Electronic address: qinchuan@pumc.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011621">Pteridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>O8M467C50G</RegistryNumber><NameOfSubstance UI="C582524">vesatolimod</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011621" MajorTopicYN="N">Pteridines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Foot and mouth disease</Keyword><Keyword MajorTopicYN="N">GS-9620</Keyword><Keyword MajorTopicYN="N">Hand</Keyword><Keyword MajorTopicYN="N">NF-&#x3ba;B and PI3K-AKT signaling pathways</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29425831</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2018.02.002</ArticleId><ArticleId IdType="pii">S0166-3542(17)30701-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>